Last reviewed · How we verify
Neuromuscular block
At a glance
| Generic name | Neuromuscular block |
|---|---|
| Also known as | Paralysis of the affected skeletal muscles anesthetic, Rocuronium |
| Sponsor | University of Florida |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Association of Sarcopenia With Rocuronium Use in Liver Transplant Recipients (NA)
- Deep Versus Moderate Neuromuscular Blocking (NA)
- Muscle and Fat Mass in Preoperative Computed Tomography and a Neuromuscular Blocking Agent Dose
- Effect of Neuromuscular Block Depth on Driving Pressure and Postoperative Respiratory Events in Abdominal Surgeries (NA)
- Safety and Efficacy of HRS-9190 Compared to Rocuronium for Bolus Maintenance in Adults (PHASE2)
- A Dose-response Study to Determine the Right Dosage of Sugammadex as a Reversal Agent of Rocuronium in Infants Between 1 and 24 Months Old (PHASE4)
- Self-Supporting Nasopharyngeal Airway (ssNPA) Treating Upper Airway Obstruction in Hypotonia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neuromuscular block CI brief — competitive landscape report
- Neuromuscular block updates RSS · CI watch RSS
- University of Florida portfolio CI